These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 9698539

  • 1. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu.
    Roh H, Pippin J, Boswell C, Drebin JA.
    J Surg Res; 1998 Jun; 77(1):85-90. PubMed ID: 9698539
    [Abstract] [Full Text] [Related]

  • 2. HER2/neu antisense targeting of human breast carcinoma.
    Roh H, Pippin JA, Green DW, Boswell CB, Hirose CT, Mokadam N, Drebin JA.
    Oncogene; 2000 Dec 11; 19(53):6138-43. PubMed ID: 11156527
    [Abstract] [Full Text] [Related]

  • 3. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu.
    Roh H, Pippin J, Drebin JA.
    Cancer Res; 2000 Feb 01; 60(3):560-5. PubMed ID: 10676637
    [Abstract] [Full Text] [Related]

  • 4. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    McGuire KP, Ngoubilly N, Neavyn M, Lanza-Jacoby S.
    J Surg Res; 2006 May 15; 132(2):208-13. PubMed ID: 16580691
    [Abstract] [Full Text] [Related]

  • 5. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation.
    Aigner A, Juhl H, Malerczyk C, Tkybusch A, Benz CC, Czubayko F.
    Oncogene; 2001 Apr 19; 20(17):2101-11. PubMed ID: 11360194
    [Abstract] [Full Text] [Related]

  • 6. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells.
    Tuna M, Chavez-Reyes A, Tari AM.
    Oncogene; 2005 Feb 24; 24(9):1648-52. PubMed ID: 15674342
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer.
    Rait AS, Pirollo KF, Rait V, Krygier JE, Xiang L, Chang EH.
    Cancer Gene Ther; 2001 Oct 24; 8(10):728-39. PubMed ID: 11687896
    [Abstract] [Full Text] [Related]

  • 9. Temporary ex vivo inhibition of the expression of the human oncogene HER2 (NEU) by a triple helix-forming oligonucleotide.
    Porumb H, Gousset H, Letellier R, Salle V, Briane D, Vassy J, Amor-Gueret M, Israël L, Taillandier E.
    Cancer Res; 1996 Feb 01; 56(3):515-22. PubMed ID: 8564964
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation.
    Brysch W, Magal E, Louis JC, Kunst M, Klinger I, Schlingensiepen R, Schlingensiepen KH.
    Cancer Gene Ther; 1994 Jun 01; 1(2):99-105. PubMed ID: 7621247
    [Abstract] [Full Text] [Related]

  • 11. Human manganese superoxide dismutase suppresses HER2/neu-mediated breast cancer malignancy.
    Chuang TC, Liu JY, Lin CT, Tang YT, Yeh MH, Chang SC, Li JW, Kao MC.
    FEBS Lett; 2007 Sep 18; 581(23):4443-9. PubMed ID: 17719580
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
    Yang DC, Jiang XP, Elliott RL, Head JF.
    Anticancer Res; 2001 Sep 18; 21(3B):1777-87. PubMed ID: 11497259
    [Abstract] [Full Text] [Related]

  • 14. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis.
    Afonja O, Juste D, Das S, Matsuhashi S, Samuels HH.
    Oncogene; 2004 Oct 21; 23(49):8135-45. PubMed ID: 15361828
    [Abstract] [Full Text] [Related]

  • 15. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
    Lu H, Qin H, Zhang Y.
    Zhonghua Zhong Liu Za Zhi; 2000 Sep 21; 22(5):370-3. PubMed ID: 11778270
    [Abstract] [Full Text] [Related]

  • 16. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
    Hanna W, Nofech-Mozes S, Kahn HJ.
    Breast J; 2007 Sep 21; 13(2):122-9. PubMed ID: 17319852
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
    Huang H, Groth J, Sossey-Alaoui K, Hawthorn L, Beall S, Geradts J.
    Clin Cancer Res; 2005 Jun 15; 11(12):4357-64. PubMed ID: 15958618
    [Abstract] [Full Text] [Related]

  • 19. Treatment of meningeal breast cancer xenografts in the rat using an anti-p185/HER2 antibody.
    Bergman I, Barmada MA, Griffin JA, Slamon DJ.
    Clin Cancer Res; 2001 Jul 15; 7(7):2050-6. PubMed ID: 11448923
    [Abstract] [Full Text] [Related]

  • 20. Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
    Peredo R, Sastre G, Serrano J, Hunter Mellado R.
    Cell Mol Biol (Noisy-le-grand); 2001 Sep 15; 47(6):1025-32. PubMed ID: 11785652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.